Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Lung Cancer. 2020 Feb 26;142:90–97. doi: 10.1016/j.lungcan.2020.02.018

Table 1.

Hazard ratios and p-values for time to progression in the training and validation datasets.

variable HR (95% CI), p-value
D1 D2 D3 D4
RRS 1.87 (1.42 – 2.2), 1.4e-05 1.66 (1.3 – 2.1), 4.7e-05 1.74 (1.32 – 2.24), 0.0024 1.83 (1.41 – 2.38), 2.3e-05
RRS + TNM staging RRS: 1.52 (1.18 – 1.94), 0.0013 stage: 2.1 (1.3 – 3.36), 0.0035 RRS: 1.49 (1.11 – 1.95), 0.0043 stage: 1.91 (1.1 – 3.87), 0.0077 RRS: 1.44 (1.24 – 2.1), 0.0077 stage: 1.84 (1.4 – 3.9), 0.0085 RRS: 1.33 (1.1 – 2.14), 0.U26 stage: 1.64 (1.5 – 4.2), 0.0092
HHS Vulnerability Disclosure